The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
|Articles|December 29, 2017
Supplements and Featured Publications
- Pseudobulbar Affect: Considerations for Managed Care Professionals
- Volume 23
- Issue 18
Posttest
Advertisement
Release date:
November 20, 2017
Expiration date:
November 20, 2018
Physician Credit
Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information
This lesson is free online. Receive instant grading and request your CE credit at www.PharmacyTimes.org.
Testing and Grading Directions
- Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest is eligible to receive CE credit.
- Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.
- To receive your credit online, go to www.PharmacyTimes.org and complete the online posttest (achieving a passing grade of 70% or better) and the online activity evaluation form before the expiration date. Your CE credit will be automatically uploaded to CPE Monitor™. Please ensure your Pharmacy Times® account is updated with your NABP e-profile ID number and your date of birth (MMDD format). Participation data will not be uploaded into CPE Monitor™ if you do not have your NABP e-profile ID number and date of birth entered into your profile on www.PharmacyTimes.org.
Articles in this issue
over 8 years ago
Pharmacotherapeutic Management of Pseudobulbar Affectover 8 years ago
Participating FacultyAdvertisement
Related to this article
A follicular lymphoma survivor shares axi-cel CAR T-cell therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improve quality of life.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5